Comparison

Cevipabulin fumarate European Partner

Item no. HY-14949C-25mg
Manufacturer MedChem Express
CASRN 849550-67-0
Amount 25 mg
Category
Type Inhibitors
Specific against other
Purity 99.97
Formula C22H22ClF5N6O5
Citations [1]Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300.<br>[2]Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both DB01229-like and Leurocristine-like properties. Cancer Chemother Pharmacol. 2009 Sep;64(4):681-9.
Smiles C[C@@H](C(F)(F)F)NC1=C(C2=C(F)C=C(OCCCNC)C=C2F)C(Cl)=NC3=NC=NN13.O=C(O)/C=C/C(O)=O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias TTI-237 fumarate
Available
Product Description
Cevipabulin fumarate (TTI-237 fumarate) is an oral, microtubule-active, antitumor compound and inhibits the binding of [3H]NSC 49842 to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2].
StorageTemperature
4°C (Powder, sealed storage, away from moisture)
Shipping
Room Temperature
Manufacturers Applications
Cancer-programmed cell death
MolecularWeight
580.89
Clinical_Information
Phase 1
Manufacturers Research_Area
Cancer
Solubility
DMSO : 50 mg/mL (ultrasonic)|H2O : 1.43 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturers Target
Microtubule/Tubulin
Pathway
Cell Cycle/DNA Damage; Cytoskeleton
Manufacturers Product type
Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close